Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
FierceBiotech2h
Corbus posts first US data on challenger to Pfizer’s ADC Padcev
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
STAT2h
Corbus reports first Western data for closely tracked ADC cancer drug
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
STAT29m
The view from overseas on tumult in U.S. science
Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rallied 5.10% to $9.48 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NA ...
MarketWatch22h
S&P 500 Pharmaceuticals Industry Index
IPC Indice de Precios Y Cotizaciones 52,926.31 108.56 0.21% ...